Profiles
51
6 sources · synthetic k = 0
Profiles are versioned counts, quantiles, and transition rates. These atlases are synthetic, so every category is kept by name. A source flagged real or sensitive suppresses cells under 11. No source row is stored.
| Profile | Version | Rows learned | Sampled | Leading pattern |
|---|---|---|---|---|
| clinical.adverse_event | v2 | 504 | 504 | moderate 54% · mild 46% |
| clinical.encounter | v2 | 42,701 | 42,701 | outpatient 100% |
| Profile | Version | Rows learned | Sampled | Leading pattern |
|---|---|---|---|---|
| commercial.touchpoint | v2 | 919 | 919 | video 27% · approved_email 26% · field 24% · webinar 23% |
| Profile | Version | Rows learned | Sampled | Leading pattern |
|---|---|---|---|---|
| distribution.inventory_ledger | v2 | 19,699 | 19,699 | DISPENSE 65% · SHIPMENT_IN 22% · OPENING 13% |
| Profile | Version | Rows learned | Sampled | Leading pattern |
|---|---|---|---|---|
| insight.attitude_trackers | v2 | 276,000 | 276,000 | 2025-01 4% · 2025-02 4% · 2025-03 4% · 2025-04 4% |
| insight.community_polls | v2 | 1,847 | 1,847 | Identifiers and measures only |
| insight.community_posts | v2 | 24,000 | 24,000 | Case discussion 23% · Discussion 23% · Peer insight 23% · Question 22% |
| insight.content_moderation | v2 | 439 | 439 | Unsubstantiated clinical claim 36% · Possible personal information 33% · Off topic 32% |
| insight.data_provenance | v2 | 7 | 7 | professionals 14% · synthetic_drugs 14% · drug_ratings 14% · survey_answers 14% |
| insight.drug_ratings | v2 | 94,000 | 94,000 | 1-5 years 33% · 6-10 years 33% · 11+ years 33% |
| insight.identity_crosswalk | v2 | 12,000 | 12,000 | deterministic_synthetic_id 100% |
| insight.member_connections | v2 | 23,000 | 23,000 | Follow 100% |
| insight.member_incentives | v2 | 53,489 | 53,489 | Paid 97% · Approved 3% |
| insight.member_interests | v2 | 23,925 | 23,925 | Identifiers and measures only |
| insight.member_profiles | v2 | 12,000 | 12,000 | Active 94% · Dormant 6% |
| insight.member_sessions | v2 | 58,000 | 58,000 | Mobile 65% · Desktop 30% · Tablet 5% |
| insight.metadata | v2 | 9 | 9 | product 11% · version 11% · generated_on 11% · synthetic 11% |
| insight.panel_participants | v2 | 400 | 400 | Attended 77% · No show 15% · Waitlist 8% |
| insight.poll_options | v2 | 7,388 | 7,388 | Identifiers and measures only |
| insight.poll_responses | v2 | 48,698 | 48,698 | Identifiers and measures only |
| insight.post_comments | v2 | 62,000 | 62,000 | Approved 100% |
| insight.post_reactions | v2 | 125,000 | 125,000 | Like 40% · Helpful 25% · Insightful 20% · Agree 15% |
| insight.professionals | v2 | 12,000 | 12,000 | Physician 94% · Physician assistant 2% · Pharmacist 2% · Nurse 1% |
| insight.qualitative_panels | v2 | 50 | 50 | Online bulletin board 46% · Video interview 28% · Online focus group 26% |
| insight.quality_checks | v2 | 6 | 6 | foreign_keys 17% · members_have_professional 17% · rating_bounds 17% · synthetic_professionals 17% |
| insight.research_clients | v2 | 42 | 42 | Fictional Research Sponsor 001 2% · Fictional Research Sponsor 002 2% · Fictional Research Sponsor 003 2% · Fictional Research Sponsor 004 2% |
| insight.research_invitations | v2 | 143,514 | 143,514 | Email digest 35% · Survey invitation 35% · App feed 15% · Community notification 10% |
| insight.research_studies | v2 | 380 | 380 | Quantitative 54% · Rapid pulse 23% · Longitudinal ATU 17% · Qualitative 6% |
| insight.specialties | v2 | 24 | 24 | Family Medicine 4% · Internal Medicine 4% · Cardiology 4% · Medical Oncology 4% |
| insight.study_participation | v2 | 67,377 | 67,377 | Complete 79% · Quota full 7% · Abandoned 7% · Partial 7% |
| insight.study_quotas | v2 | 760 | 760 | Profession 100% |
| insight.survey_answers | v2 | 267,445 | 267,445 | Identifiers and measures only |
| insight.survey_questions | v2 | 1,900 | 1,900 | Often|Sometimes|Rarely|Never 20% · Efficacy|Safety|Access|Adherence 20% |
| insight.survey_screeners | v2 | 78,476 | 78,476 | Quota full 5% · Insufficient patient volume 5% · Practice setting not qualified 5% |
| insight.synthetic_drugs | v2 | 120 | 120 | Fictional Therapy 001 1% · Fictional Therapy 002 1% · Fictional Therapy 003 1% · Fictional Therapy 004 1% |
| insight.therapeutic_areas | v2 | 12 | 12 | Oncology 8% · Cardiovascular 8% · Diabetes 8% · Immunology 8% |
| insight.topics | v2 | 12 | 12 | Clinical practice 8% · Treatment sequencing 8% · Payer restrictions 8% · Emerging evidence 8% |
| insight.treatment_patterns | v2 | 96,000 | 96,000 | 2025-01 13% · 2025-04 13% · 2025-07 13% · 2025-10 13% |
| insight.verification_events | v2 | 12,000 | 12,000 | Synthetic license confirmation 100% |
| Profile | Version | Rows learned | Sampled | Leading pattern |
|---|---|---|---|---|
| patient.journey_event | v2 | 72,714 | 72,714 | PRESCRIPTION_ORDER 42% · ACCESS_FAILURE 24% · DISPENSED 18% · DIAGNOSIS 17% |
| patient.journey_transitions | v2 | 60,714 | 60,714 | Identifiers and measures only |
| patient.treatment_episode | v2 | 9,887 | 9,887 | new_therapy 86% · switch 14% |
| Profile | Version | Rows learned | Sampled | Leading pattern |
|---|---|---|---|---|
| rx.claim_attempt | v2 | 38,578 | 38,578 | B1 100% |
| rx.drug | v2 | 69 | 69 | DERM 17% · ONC 17% · RESP 16% · MHEALTH 14% |
| rx.formulary_at_order | v2 | 30,357 | 30,357 | Covered 59% · Not covered 41% |
| rx.hco | v2 | 1,189 | 1,189 | Multi-specialty Group 22% · Primary Care Group 22% · Hospital 11% · Ambulatory Surgery Center 9% |
| rx.hcp | v2 | 1,500 | 1,500 | FM 13% · IM 9% · CARD 7% · NP 6% |
| rx.orders_per_patient | v2 | 12,000 | 12,000 | Identifiers and measures only |
| rx.patient | v2 | 12,000 | 12,000 | F 51% · M 49% |
| rx.plan | v2 | 240 | 240 | Commercial 30% · Medicare Advantage-PD 23% · Medicaid Managed Care 13% · Exchange 12% |
| rx.prescription_order | v2 | 30,357 | 30,357 | ISSUED 100% |
Each golden release is scored against the atlas profile. A later version that moves past a threshold is a drift, not a silent rewrite.
| Release | Table | Metric | Score | Threshold | Gate |
|---|---|---|---|---|---|
| nsclc-metex14_1.0 | drug | js_ta_code | 0.032 | 0.22 | pass |
| nsclc-metex14_1.0 | formulary | js_coverage | 0.000 | 0.08 | pass |
| nsclc-metex14_1.0 | hcp | js_specialty | 0.002 | 0.12 | pass |
| nsclc-metex14_1.0 | hcp | js_state | 0.002 | 0.12 | pass |
| nsclc-metex14_1.0 | journey | sequence_violation | 0.000 | 0.05 | pass |
| nsclc-metex14_1.0 | patient | ks_birth_year | 0.044 | 0.35 | pass |
| nsclc-metex14_1.0 | plan | js_channel | 0.003 | 0.12 | pass |
| psoriasis-biologics_1.0 | drug | js_ta_code | 0.032 | 0.22 | pass |
| psoriasis-biologics_1.0 | formulary | js_coverage | 0.000 | 0.08 | pass |
| psoriasis-biologics_1.0 | hcp | js_specialty | 0.002 | 0.12 | pass |
| psoriasis-biologics_1.0 | hcp | js_state | 0.002 | 0.12 | pass |
| psoriasis-biologics_1.0 | journey | sequence_violation | 0.000 | 0.05 | pass |
| psoriasis-biologics_1.0 | patient | ks_birth_year | 0.044 | 0.35 | pass |
| psoriasis-biologics_1.0 | plan | js_channel | 0.003 | 0.12 | pass |
rel_nsclc-metex14_1.0 · 7 checks · widest distance 0.044
rel_psoriasis-biologics_1.0 · 7 checks · widest distance 0.044
Version 1 is the baseline learned from the released atlas files on 2026-11-20. The next hive run profiles the new release and compares it with this baseline.
| Release | Table | Learned | Generated | Ratio |
|---|---|---|---|---|
| nsclc | attitude_trackers | 276,000 | 55,200 | 0.20 |
| nsclc | survey_answers | 267,445 | 53,489 | 0.20 |
| nsclc | research_invitations | 143,514 | 28,703 | 0.20 |
| nsclc | post_reactions | 125,000 | 25,000 | 0.20 |
| nsclc | treatment_patterns | 96,000 | 19,200 | 0.20 |
| nsclc | drug_ratings | 94,000 | 18,800 | 0.20 |
| nsclc | survey_screeners | 78,476 | 15,695 | 0.20 |
| nsclc | study_participation | 67,377 | 13,475 | 0.20 |
| nsclc | post_comments | 62,000 | 12,400 | 0.20 |
| nsclc | member_sessions | 58,000 | 11,600 | 0.20 |
| nsclc | member_incentives | 53,489 | 10,698 | 0.20 |
| nsclc | poll_responses | 48,698 | 9,740 | 0.20 |
| nsclc | community_posts | 24,000 | 4,800 | 0.20 |
| nsclc | member_interests | 23,925 | 4,785 | 0.20 |
| nsclc | member_connections | 23,000 | 4,600 | 0.20 |
| nsclc | professionals | 12,000 | 2,400 | 0.20 |
| nsclc | identity_crosswalk | 12,000 | 2,400 | 0.20 |
| nsclc | member_profiles | 12,000 | 2,400 | 0.20 |
| nsclc | verification_events | 12,000 | 2,400 | 0.20 |
| nsclc | poll_options | 7,388 | 1,478 | 0.20 |
| nsclc | content_moderation | 439 | 439 | 1.00 |
| nsclc | panel_participants | 400 | 400 | 1.00 |
| nsclc | research_studies | 380 | 380 | 1.00 |
| nsclc | survey_questions | 1,900 | 380 | 0.20 |
| nsclc | community_polls | 1,847 | 369 | 0.20 |
| nsclc | study_quotas | 760 | 152 | 0.20 |
| nsclc | synthetic_drugs | 120 | 120 | 1.00 |
| nsclc | qualitative_panels | 50 | 50 | 1.00 |
| nsclc | research_clients | 42 | 42 | 1.00 |
| nsclc | specialties | 24 | 24 | 1.00 |
| nsclc | topics | 12 | 12 | 1.00 |
| nsclc | therapeutic_areas | 12 | 12 | 1.00 |
| nsclc | metadata | 9 | 9 | 1.00 |
| nsclc | data_provenance | 7 | 7 | 1.00 |
| nsclc | quality_checks | 6 | 6 | 1.00 |
| psoriasis | attitude_trackers | 276,000 | 22,080 | 0.08 |
| psoriasis | survey_answers | 267,445 | 21,396 | 0.08 |
| psoriasis | research_invitations | 143,514 | 11,481 | 0.08 |
| psoriasis | post_reactions | 125,000 | 10,000 | 0.08 |
| psoriasis | treatment_patterns | 96,000 | 7,680 | 0.08 |
| psoriasis | drug_ratings | 94,000 | 7,520 | 0.08 |
| psoriasis | survey_screeners | 78,476 | 6,278 | 0.08 |
| psoriasis | study_participation | 67,377 | 5,390 | 0.08 |
| psoriasis | post_comments | 62,000 | 4,960 | 0.08 |
| psoriasis | member_sessions | 58,000 | 4,640 | 0.08 |
| psoriasis | member_incentives | 53,489 | 4,279 | 0.08 |
| psoriasis | poll_responses | 48,698 | 3,896 | 0.08 |
| psoriasis | community_posts | 24,000 | 1,920 | 0.08 |
| psoriasis | member_interests | 23,925 | 1,914 | 0.08 |
| psoriasis | member_connections | 23,000 | 1,840 | 0.08 |
| psoriasis | professionals | 12,000 | 960 | 0.08 |
| psoriasis | member_profiles | 12,000 | 960 | 0.08 |
| psoriasis | identity_crosswalk | 12,000 | 960 | 0.08 |
| psoriasis | verification_events | 12,000 | 960 | 0.08 |
| psoriasis | poll_options | 7,388 | 591 | 0.08 |
| psoriasis | content_moderation | 439 | 439 | 1.00 |
| psoriasis | panel_participants | 400 | 400 | 1.00 |
| psoriasis | research_studies | 380 | 380 | 1.00 |
| psoriasis | survey_questions | 1,900 | 152 | 0.08 |
| psoriasis | community_polls | 1,847 | 148 | 0.08 |
| psoriasis | synthetic_drugs | 120 | 120 | 1.00 |
| psoriasis | study_quotas | 760 | 61 | 0.08 |
| psoriasis | qualitative_panels | 50 | 50 | 1.00 |
| psoriasis | research_clients | 42 | 42 | 1.00 |
| psoriasis | specialties | 24 | 24 | 1.00 |
| psoriasis | topics | 12 | 12 | 1.00 |
| psoriasis | therapeutic_areas | 12 | 12 | 1.00 |
| psoriasis | metadata | 9 | 9 | 1.00 |
| psoriasis | data_provenance | 7 | 7 | 1.00 |
| psoriasis | quality_checks | 6 | 6 | 1.00 |